Abstract. Most current anticancer drugs have shown excellent therapeutic effects on human oral squamous cell carcinoma (OSCC), but they also produce potent cytotoxicity in normal oral keratinocytes. This review article summarizes our extensive research of tumor specificity and keratinocyte toxicity of nine groups of compounds synthesized in our laboratory. Among a total of 133 compounds, (E)-3-[2-(4-hydroxyphenyl)ethenyl]-6-methoxy-4H-1-benzopyran-4-one [3] (classified as 3-styrylchromones), (E)-3-[2-(4-chlorophenyl)ethenyl]-7-methoxy-2H-1-benzopyran [4] (classified as 3-styryl-2H-chromenes) showed the highest tumor specificity with the least keratinocyte toxicity.
Compound [3] induced apoptotic cell death in a human OSCC cell line, possibly by down-regulating the glycerophospholipid pathway. Quantitative structure−activity relationship analysis demonstrated that the tumor specificities of [3] and [4] Previous studies have focused on the mechanism of apoptosis induction by anticancer drugs rather than the demonstration of their tumor specificity. Most anticancer drugs induce similar morphological changes to those observed during the developmental process (eliminating unnecessary tissues and harmful cells).
Problems of Current Anticancer Drugs
It is well known that administration of anticancer agents induces skin toxicity (1) (2) (3) (4) (5) (6) (7) . This prompted us to re-evaluate the cytotoxicity and tumor specificity of anticancer drugs. For this purpose, we established an in vitro assay system, using four human oral squamous cell carcinoma (OSCC) cell lines We first investigated the tumor specificity of anticancer drugs using OSCC cell lines and normal mesenchymal cells (MCs) (referred to as System 1). Many anticancer drugs, such as docetaxel, 5-fluorouracil (5-FU), methotrexate, mitomicin C, etoposide, daunorubicin, doxorubicin, SN-38 (active metabolite of irinotecan), camptothecin and gefitinib, showed excellent specificity (TS=10-1000) ( Figure 2B ) (8) . This validated the present method for evaluating anticancer activity.
We next evaluated the tumor specificity of anticancer drugs using OSCC cell lines and normal epithelial cells (ECs.) (referred to as System 2). In this case, anticancer agents showed cytotoxicity to both of these cell types to comparable extents, producing a much lower TS value (9) . It was unexpected that doxorubicin would induce apoptosis [loss of cell surface microvilli, chromatin condensation, nuclear fragmentation ( Figure 3A ) and caspase-3 activation ( Figure 3B )] in HOKs (9) . It is therefore imperative to explore new anticancer drugs with less keratinocyte toxicity.
In Search of Antitumor Agents with Less Toxicity to Keratinocytes
We have synthesized a total of 133 compounds, which are classified into nine groups, by introducing various functional groups into distinct backbone structures (Figure 4) . The most potent compound in each group was: (2E)-3-(3,4-dihydroxy-ANTICANCER RESEARCH 37: 5919-5924 (2017) 5920 
Estimation of TS by Chemical Descriptors
Six descriptors that correspond greatly with cytotoxicity against normal cells (N) and tumor cells (T), and with tumor specificity (T−N) of nine groups of compounds are listed in Table I . Generally, these descriptors did not overlap with each other. Tumor specificity of 3-styrylchromones was well corrected with molecular size (12) . T−N can be estimated by molecular diameter (largest value in the distance matrix defined by the elements Dij), vsurf_DD23 (interaction with hydrophobic probe assumed surrounding the molecule) and R3 OH (4'-hydroxy substitution in the phenyl group of styryl moiety) as: T−N=0.607(±0.169)diameter -0.121 (±0.035)vsurf_DD23 + 1.11 (±0.235)R3OH -7.17 (±2.26), with n=15, R 2 =0.764, Q 2 =0.570. s=0.308 ( Figure 5A ).
Tumor selectivity of 3-styryl-2H-chromenes correlated well with six descriptors (std_dim3, BCUT_SLOGP_1, vsurf_D4, vsurf_R, vsurf_D5 and E_oop) which reflect structure connectivity and conformation, hydrophobicity, surface rugosity and out-of-plane potential energy (Table I ). The T−N value of [4] can be estimated using two descriptors (vsurf_R and E_oop) Sugita et al: Search for New Types of Anticancer Drugs (Review) 5921 Figure (9) (12) and (14) .
Keratinocyte toxicity induced by doxorubicin (DXR). HSC-2 cells were incubated for 0 or 24 h with 10 μM doxorubicin (A), or with different concentrations of doxorubicin (B), and then processed for observation under transmission electron microscopy (A) or subjected to western blot analysis (B). Cited from
as: T−N=32.1(±4.39)vsurf_R + 121(±17)E_oop -46.1(±6.2), with n=16, R 2 =0.870, Q 2 =0.821, s=0.145 ( Figure 5B ).
Future Directions
In our work, we have demonstrated that [3] and [4] are two new compounds that showed the highest TS and potencyselectivity expression values among the compounds tested, and they exhibited much less keratinocyte toxicity compared to doxorubicin and 5-FU (Figure 4 ). Chemical modification of these lead compounds by introduction of appropriate functional groups is a crucial step towards manufacturing new types of anticancer drugs with reduced keratinocyte toxicity.
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